- Home
- DHY vs ZVRA Comparison
DHY vs ZVRA Comparison
Compare DHY & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$8.93
Company Overview
Basic Information| Metric | DHY | ZVRA |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.2M | 478.0M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | DHY | ZVRA |
|---|---|---|
| Price | $2.02 | $8.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.71 |
| AVG Volume (30 Days) | 569.1K | ★ 955.1K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 9.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | N/A | ★ $84,388,000.00 |
| Revenue This Year | N/A | $333.64 |
| Revenue Next Year | N/A | $43.58 |
| P/E Ratio | ★ N/A | $16.79 |
| Revenue Growth | N/A | ★ 244.60 |
| 52 Week Low | $1.77 | $6.19 |
| 52 Week High | $2.08 | $13.16 |
Technical Indicators
Market Signals| Indicator | DHY | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 54.78 | 54.49 |
| Support Level | $2.01 | $8.08 |
| Resistance Level | $2.05 | $9.24 |
| Average True Range (ATR) | 0.02 | 0.41 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 50.00 | 73.28 |
Price Performance
Historical Comparison DHY
ZVRA
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.